Small molecule NCE Platform therapeutic potential Mortality data in 1 st TPP
|
|
- Jerome Douglas
- 5 years ago
- Views:
Transcription
1 Small molecule NCE Platform therapeutic potential Mortality data in 1 st TPP
2 Headlines Novel combined anti- inflammatory and anti- infective Re- profiles cytokines - IL- 6, IL- 8, IL- 10 Broad- spectrum anti- infective without resistance Life- saving - adults and children
3 Product pipeline : clinical + discovery Discovery Phase 1 + Pre- clinical Clinical Proof of Concept Phase 3 PAC- B PAC- A PAC- G Orphan burns treatment : mortality data POC Surgical site treatment : infection reduction data POC Non- healing wounds: In human POC PAC- I Orphan VAP treatment : Healthy volunteers PAC- IC Cystic fibrosis PAC- CP Chronic pain PAC- G Fibrosis
4 anti- inflammatory + anti- fibrosis + pro- healing Minimal scar & Normal hair growth Intractable post- radiotherapy fistula
5 Orphan class burns treatment (2 nd 3 rd 4 th degree burns requiring surgery & grafting) Proven life- saving treatment for adults and children Prevents and reverses inflammatory sepsis Effective against multi drug resistant pathogens Reduces need for surgical intervention Significantly reduces scarring
6 Burns Market Size Mean Cost per Patient Mean Length of Stay Incidence Rate (per 100,000) 20, Days , billion 493, billion Projections based on Maasstad Hospital, Rotterdam
7 Study Group (PAC- B) Broomfield survival data vs comparator data
8 Anti- inflammatory + anti- infective + rapid healing + scar reduction Inflammation modulation Simultaneous cytokine re- profiling action IL- 6 inhibition IL- 8 inhibition IL- 10 unaffected Ratio correction prevents scar formation Antimicrobial efficacy Effective against drug resistant pathogens Kills Ps. Aeruginosa Kills MRSA, C. Diff, Candida Neutralizes virulence factors Preserves antibiotics of last- resort
9 Market potential and IP strategy Orphan class EU / FDA Deep partial thickness and full thickness burns In development Ventilator pneumonia Cystic fibrosis Patent protection NCE Method of production First filing 2010 with first grants Marks & Clerk since inception
10 Burns Market Size Mean Cost per Patient Mean Length of Stay Incidence Rate (per 100,000) 20, Days , billion 493, billion Projections based on Maasstad Hospital, Rotterdam
11 Competitor Analysis - Debridement Chemical Debridement Direct Competitor No damage to healthy tissue No surgery Fast eschar removal Targets collagen Gentle on viable cells Suitable for burns <15% TBSA Sensitisation with 2 nd application Allergic reactions are common No antibacterial properties Mechanical Debridement 3225 Less damage to healthy tissue Reduced dressing changes Faster healing Surgical theatre required Hard to manipulate in small areas Surgical Debridement 4614 Fast Effective Surgery and anesthesia required Traumatic, resulting in blood loss Very non- specific Prices shown are per treatment/per day
12 Judge Business School Valuation Non- Financial Value Anti- inflammatory and Anti- microbial action Improved patient outcomes Meets high unmet clinical need Financial Value Orphan Burns Only 200M 300M Total Burns 360M 500M Given asset value range based on base case scenario High financial returns expected on investment even in worst case scenario (extremely unlikely to happen) We strongly recommend investment in HypoStream
13 Hypo- Stream efficacy, safety and patent: Strategic partners The St Andrew s Centre Regional Burns Intensive Care Unit MHRA consultation EMA COMP U. Cambridge U. Cranfield U. Anglia Ruskin Broomfield Hospital Burns unit U. Cardiff School of Pharmacy U. Cardiff Medical School Marks & Clerk patent attorneys
14 Product pipeline : clinical + discovery Discovery Phase 1 + Pre- clinical Clinical Proof of Concept Phase 3 PAC- B PAC- A PAC- G Orphan burns treatment : mortality data POC Surgical site treatment : infection reduction data POC Non- healing wounds: In human POC PAC- I Orphan VAP treatment : Healthy volunteers PAC- IC Cystic fibrosis PAC- CP Chronic pain PAC- G Fibrosis
15 Management & development team CEO & Founder - Myles Dakin: Oral & Trauma surgery, research, teaching and private specialist practice UK and USA 25 years. Chairman - Keiron Sparrowhawk: GSK, PriceSpective, MyCognition, U. Cambridge JBS. 39 years in drug development & market access. CCO - Lee Farnsworth: 19 years at major pharma. Most recently Commercial VP EAME region at Allergan. CFO - Julian Dakin: 30 years corporate banking. USA, UK and Europe. CLO - Marc Dalby: Barrister and solicitor. Formerly legal counsel MSD Academic collaborators: Professor K Harding (Chronic Ulcers + wound healing); Professor P Dziewulski (Burns + plastic surgery); Professor R Aspinal (Immunology + ageing studies); Professor Martin Bootman (intra- cellular signaling + drug action mechanism); Dr N Brown (Microbiology + hospital infection control); Mr N Hall (General surgery).
16 Hypo- Stream A.P.I Cytokine re- profiling Toxin & pathogen neutralisation
17 Multiple data- sets offer multiple therapies
18 Infection elimination Enhanced healing 12 years safety & efficacy +400 treatments
19 Inflammation pathophysiology is universal in all tissue systems
20 Anti- inflammatory + anti- infective + rapid healing + scar reduction Inflammation modulation Simultaneous cytokine re- profiling IL- 6 inhibition IL- 8 inhibition IL- 10 unaffected Ratio correction prevents scar formation Antimicrobial efficacy Effective against drug resistant pathogens Kills Ps. Aeruginosa Kills MRSA, C. Diff, Candida Neutralizes virulence factors Preserves antibiotics of last- resort
21 Healing in non- healing wounds Minimal scar & Normal hair growth Intractable post- radiotherapy fistula
22 Resolution of Refractory leg ulcers
23 Unique mechanism profile Inflammatory cascade modulation Healing cascade modulation Modulation of scar formation Disrupts pathogen function (no known resistance) Safe, tested in humans >400 patients Data on request
24 Multi- cytokine modulation replicates innate resolution of inflammation Functional inhibition of IL- 6 Functional inhibition of IL- 8 No impact on IL- 10 Differential action on proteins DNA is shielded
25 Multi- cytokine re- profiling: Aspinall, 2014 Data on file: Hypo- Stream 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Function of IL- 6, IL- 8 & IL minutes 5 minutes 10 minutes 15 minutes 20 minutes 25 minutes 30 minutes 1. IL- 6 & IL- 8 inhibition 2. IL- 10 maintained function IL- 6 & IL- 8 function IL- 10 Function Aspinall R U. IL- 6, IL- 8, IL- 10 Cytokine assay
26 Cytokine re- profiling = scar prevention Cytokine hypothesis defines scar free healing milieu Illustration From King et al, Regenerative Wound Healing: The role of Interleukin 10 Advances in wound care. 2014; 3(4):
27 Nosocomial infection Global unmet need - Human cost - Economic cost
28 Zimlichman et al. J. Am Med. Assoc. Intern Medicine. 2013; 173(22): SSIs comprise 33.7% of the total US$9.8 billion cost of HAI Each SSI was responsible for a cost of US$20,700 and an additional 11.2 additional hospital day stays. MRSA SSIs cost is US$42,300 with an additional 23.0 hospital days stayed.
29 Additional therapy validation Effective in surgical site treatment (n=387) elimination of SSI and failed healing vs control (28% vs 0.7%) Intractable wounds. Venous ulcers, radiotherapy fistula
30 Surgical site data 20x reduction in SSI in over 350 patient study Reduction of infection from 28% to 0.7% SOC PAC % surgical site infection
31 Product pipeline : clinical + discovery Discovery Phase 1 + Pre- clinical Clinical Proof of Concept Phase 3 PAC- B PAC- A PAC- G Orphan burns treatment : compelling data POC Surgical site treatment : infection reduction data POC Non- healing wounds: In human POC PAC- I Orphan VAP treatment : Healthy volunteers PAC- IC Cystic fibrosis PAC- CP Chronic pain PAC- G I.B.D.
32 Hypo- Stream efficacy, safety and patent: Strategic partners The St Andrew s Centre Regional Burns Intensive Care Unit MHRA consultation EMA COMP U. Cambridge U. Cranfield U. Anglia Ruskin Broomfield Hospital Burns unit U. Cardiff School of Pharmacy U. Cardiff Medical School Marks & Clerk patent attorneys
33 Management & development team CEO & Founder - Myles Dakin: Oral & Trauma surgery, research, teaching and private specialist practice UK and USA 25 years. Chairman - Keiron Sparrowhawk: GSK, PriceSpective, MyCognition, U. Cambridge JBS. 39 years in drug development & market access. CCO - Lee Farnsworth: 19 years at major pharma. Most recently Commercial VP EAME region at Allergan. CFO - Julian Dakin: 30 years corporate banking. USA, UK and Europe. CLO - Marc Dalby: Barrister and solicitor. Formerly legal counsel MSD Academic collaborators: Professor K Harding (Chronic Ulcers + wound healing); Professor P Dziewulski (Burns + plastic surgery); Professor R Aspinal (Immunology + ageing studies); Professor Martin Bootman (intra- cellular signaling + drug action mechanism); Dr N Brown (Microbiology + hospital infection control); Mr N Hall (General surgery).
34 Contact Hypo- Stream Ltd 9 Beech House Melbourn Science Park Melbourn SG8 6HB Web: Myles Dakin: Julian Dakin: stream.com md@hypo- stream.com jd@hypo- stream.com Hypo- Stream Ltd College of Medicine Institute of Life Science Singleton Park Swansea SA2 8PP
- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes
Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options
More informationCompany Presentation. Nasdaq: MDWD. June Gal Cohen, President & CEO
Company Presentation June 2015 Nasdaq: MDWD Gal Cohen, President & CEO Cautionary note Regarding Forward-looking statements This presentation contains forward-looking statements within the meaning of Section
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationCompany Presentation March Nasdaq: MDWD
Company Presentation March 2018 Nasdaq: MDWD Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the U.S. Securities
More informationImmunity for Life TM. Third Quarter CEO Lars Viksmoen CFO Finn Samuelsen. 31 October 2007
Immunity for Life TM Third Quarter 2007 CEO Lars Viksmoen CFO Finn Samuelsen 31 October 2007 Operational Highlights for Q3 2007 Clinical phase III study with SBG for treatment of diabetic ulcers; enrolment
More informationMulti-Center Clinical Results with PluroGel PSSD in Chronic Wounds
Multi-Center Clinical Results with PluroGel PSSD in Chronic Wounds Presented at a Satellite Symposium during the European Wound Management Association (EWMA) 2012 24 May 2012 Vienna, Austria Multi-Center
More informationAradigm Corporation. A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008
Aradigm Corporation A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008 Safe Harbor Statement This presentation contains forward-looking statements
More informationCastle Creek Pharmaceuticals
Castle Creek Pharmaceuticals Dermatology Summit Entrepreneurial Showcase 2018 Michael Derby, CEO January 7, 2018 Castle Creek Pharma Driving innovation in dermatology We are a high-growth biotech company
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More informationWednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address
Advanced Molecular Diagnostic Systems The Walter and Eliza Hall Biotechnology Centre, 4 Research Avenue, La Trobe R&D Park, Bundoora, Victoria 3083 T: +61 (0)3 9345 2127 F: +61 (0)3 9345 2242 Wednesday
More informationInspired. by the Body.
Inspired. by the Body. Powered. by Electricity. Energized. by Results. Inspired. by the Body. Powered. by Electricity. Energized. by Results. INTRODUCING Procellera Procellera from Vomaris is the world
More informationTherapeutic products. for. respiratory and autoimmune diseases
Therapeutic products for respiratory and autoimmune diseases Annual General Meeting November 2005 Highlights Bronchitol Aridol Autoimmune disease Manufacturing Bronchitol: Entering Phase III Successful
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationCorporate Presentation. October 2017
AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking
More informationPresentation First quarter 2006
Immunity for Life TM Presentation First quarter 2006 CEO Gunnar Rørstad CFO Finn Samuelsen 10 May 2006 Highlights - operations Inclusion of patients almost completed in the the phase II clinical trial
More informationI ve a drawer full of dressings i don t know how to use!
I ve a drawer full of dressings i don t know how to use! Introduction: Originating from battlefield medicine much of what we use today is an evolution of material science combined with our understanding
More informationSurgical Wounds & Incisions
Surgical Wounds & Incisions A Comprehensive Review Assessment & Management Alex Khan APRN ACNS-BC MSN CWCN CFCN WCN-C Advanced Practice Nurse / Adult Clinical Nurse Specialist www.woundcarenurses.org 1
More informationABBVIE VENTURES VISION. Drive strategic returns to AbbVie as a key constituent of overall corporate strategy
ABBVIE VENTURES ABBVIE VENTURES VISION Drive strategic returns to AbbVie as a key constituent of overall corporate strategy Early access to external innovation with a long-term horizon to generate meaningful
More informationYour Partner in Healing
Your Partner in Healing Euromed provides all functions necessary for market-ready hydrocolloid wound dressings. With fully integrated services, Euromed is one of a select few custom hydrocolloid manufacturers
More informationIntroducing Mepilex Transfer Ag It all adds up to undisturbed healing. Antimicrobial wound contact layer with Safetac technology
Introducing Mepilex Transfer Ag It all adds up to undisturbed healing Antimicrobial wound contact layer with Safetac technology Mepilex Transfer Ag Help the body heal The importance of less pain The body
More informationTopical antimicrobial agents in wound care. Professor Val Edwards-Jones Manchester Metropolitan University UK
Topical antimicrobial agents in wound care Professor Val Edwards-Jones Manchester Metropolitan University UK Antimicrobial agents Antibacterial agents Antifungal agents Antiviral agents Antiparasitic agents?others
More informationAGM Presentation For the year to 30 September February 2016
AGM Presentation For the year to 30 September 2015 25 February 2016 11 Forward Looking Statements This presentation includes forward-looking statements. These forward-looking statements involve known and
More informationForward-looking Statement Disclaimer
Forward-looking Statement Disclaimer This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to
More informationArglaes provides a seven-day, non-cytotoxic barrier against infection
Arglaes provides a seven-day, non-cytotoxic barrier against infection Arglaes Controlled-Release Silver Technology Reduce bioburden with Arglaes Silver Barrier Dressings Antimicrobial Arglaes began the
More informationSmart Solutions for Serious Wounds. An advanced bilayer dermal regeneration matrix FDA approved for the treatment of diabetic foot ulcers.
Smart Solutions for Serious Wounds An advanced bilayer dermal regeneration matrix FDA approved for the treatment of diabetic foot ulcers. A New Approach to Diabetic Foot Ulcer Care Supported by Over Two
More informationi-bodies a new class of protein therapeutics to treat fibrosis
i-bodies a new class of protein therapeutics to treat fibrosis BIOSHARES JULY 2017 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment in AdAlta is subject
More informationLower Extremity Wound Evaluation and Treatment
Lower Extremity Wound Evaluation and Treatment Boni-Jo Silbernagel, DPM Describe effective lower extremity wound evaluation and treatment. Discuss changes in theories of treatment in wound care and implications
More informationThe VERSAJET II Hydrosurgery System
Precise Excision The VERSAJET II Hydrosurgery System The VERSAJET II Hydrosurgery System The VERSAJET II system enables a surgeon to precisely select, excise and evacuate nonviable tissue, bacteria and
More informationApplication Guide for Full-Thickness Wounds
Application Guide for Full-Thickness Wounds PriMatrix Dermal Repair Scaffold PriMatrix Ag Antimicrobial Dermal Repair Scaffold Application Guide for Full Thickness Wounds PriMatrix is a unique dermal repair
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationGLG Pharma, LLC. A Specialty Pharmaceutical Company developing the next generation of targeted drugs
GLG Pharma, LLC A Specialty Pharmaceutical Company developing the next generation of targeted drugs Privately Held Company Summary Experienced Management Team Development stage full spectrum Marketed Products:
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationMEDICAL CANNABIS COMPANY
MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - June 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward looking statements
More informationNovoSorb BTM. A unique synthetic biodegradable wound scaffold. Regenerating tissue. Changing lives.
NovoSorb BTM A unique synthetic biodegradable wound scaffold Regenerating tissue. Changing lives. Overview NovoSorb BTM is a unique synthetic biodegradable wound scaffold that delivers good cosmetic and
More informationFuture Leaders in the Biotech Industry. Lee Bendekgey, SVP, CFO & General Counsel April 7, 2005
Future Leaders in the Biotech Industry Lee Bendekgey, SVP, CFO & General Counsel April 7, 2005 Safe Harbor This presentation contains "forward-looking statements" regarding potential use of Nuvelo clinical
More informationNANO MICROBE ZAPPER (NMZ): A NOVEL ECO-SAFE NANOPARTICLE MEDIATED ANTIMICROBIAL KILLER
NANO MICROBE ZAPPER (NMZ): A NOVEL ECO-SAFE NANOPARTICLE MEDIATED ANTIMICROBIAL KILLER Raghuraman Kannan, PhD Assistant Professor of Radiology Michael J and Sharon R Bukstein Distinguished Fellow in Cancer
More informationPartnering the burn community
* At smith&nephew we seek imaginative solutions that improve wound outcomes for patients and at the same time conserve resources for healthcare systems. Partnering the burn community Dedicated to the management
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Jefferies Global Healthcare Conference June 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationAgenda (45 minutes) Some questions for you. Which wound dressing? Dressing categories/types. Summary
Dressing selection Agenda (45 minutes) Some questions for you. Which wound dressing? Dressing categories/types Summary Which wound dressing poster Ref: Which wound dressing? Practice Nursing, September
More informationAbilar Questions and Answers
Abilar Questions and Answers Question Answer Product Information What is Abilar Resin Salve? What are the main properties of Abilar? How is Resin different from colophony (rosin)? Abilar Resin Salve is
More informationOraSure Technologies. JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014
OraSure Technologies JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014 Forward-Looking Statements These slides and the associated presentation contain certain forward-looking statements, including
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More informationEWMA Educational Development Programme. Curriculum Development Project. Education Module. Wound Infection
EWMA Educational Development Programme Curriculum Development Project Education Module Wound Infection Latest revision: February 2014 ABOUT THE EWMA EDUCATIONAL DEVELOPMENT PROGRAMME The Programme is designed
More informationLeading R&D pipeline with proven technology. Partners. Injection and drop-based allergy immunotherapy products
ALK at a glance The leading allergy immunotherapy specialist 33% of global allergy immunotherapy market Leading R&D pipeline with proven technology Strategic partnerships to globalise SLIT- tablet portfolio
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationSAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationTSX Venture: RVV OTCQB: RVVTF
TSX Venture: RVV OTCQB: RVVTF The image part with relationship ID rid3 was not found in the file. 2017 Annual General and Special Meeting of Shareholders December 19, 2017 Revive Therapeutics Ltd. Office:
More informationThe medicinal use of honey has been known since ancient
THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 13, Number 4, 2007, pp. 439 441 Mary Ann Liebert, Inc. DOI: 10.1089/acm.2007.6366 Bactericidal Activity of Different Types of Honey Against
More informationInterim Results of Expanded Access Program of AB-SA01 and AB-PA01 for Treatment of Serious and Life-threatening S. aureus and P. aeruginosa Infections
Advancing bacteriophage therapeutics for patients with antibioticresistant infections Interim Results of Expanded Access Program of AB-SA01 and AB-PA01 for Treatment of Serious and Life-threatening S.
More informationNM-96: A Small Molecule For The! Treatment of Acute Sickle Crisis!! Life Science Summit 10/29/14! Steven Isaacman, Ph.D.!
www.nanometicslab.com! NM-96: A Small Molecule For The! Treatment of Acute Sickle Crisis!! Life Science Summit 10/29/14! Steven Isaacman, Ph.D.!! Founder & CEO!! Nanometics LLC! About Nanometics! Founded
More informationCompany presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018
Company presentation SEB Nordic Seminar Bella Sky, Copenhagen Carsten Hellmann, President & CEO 9 January 2018 Allergy: a global disease with a large unmet need >500 million people affected by allergic
More informationBioDiem to present at Hong Kong biotech investment forum
ASX Announcement BIODIEM LTD ABN 20 096 845 993 Suite 3, Level 11, 470 Collins Street, Melbourne, Victoria, 3000 Australia Phone: +613 9613 4100 Web: www.biodiem.com BioDiem to present at Hong Kong biotech
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationA Broad Clinical Pipeline of Innovative Diabetes / Renal & Oncology Programs. European Business Development Conference Düsseldorf 24 Sept 2013
A Broad Clinical Pipeline of Innovative Diabetes / Renal & Oncology Programs European Business Development Conference Düsseldorf 24 Sept 2013 Key facts about NOXXON Developing a new class of proprietary
More informationPersonalized medecine Biomarker
Patient Disease Diagnosis Risk prediction Personalized medecine Biomarker Targeted therapies Diagnostic Theranostic: Efficay Toxicity Treatment 1 THE CASE FOR PERSONALIZED MEDICINE IS COMPELLING.. Toxicity
More informationRP-G28: First in Class Rx for Treatment of Lactose Intolerance. March 2013
RP-G28: First in Class Rx for Treatment of Lactose Intolerance March 2013 Value Proposition Specialty pharmaceutical company, focused on GI disease Core science based on colonic adaptation First company
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer September 2013 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationDutch Life Sciences November 24 th, Erik Dam, CBO
Dutch Life Sciences November 24 th, 2016 Erik Dam, CBO Unmet need for food ingredients with clinically proven health benefits Consumers want healthy foods and will pay more for them (Forbes 2015) Global
More informationCorporate Presentation
Corporate Presentation March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States Private Securities
More informationDelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)
Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology
More informationTSX Venture: RVV OTCQB: RVVTF
TSX Venture: RVV OTCQB: RVVTF Corporate Presentation June 2018 Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com FORWARD LOOKING STATEMENTS Certain statements contained in this
More informationProduct Development for Public Health & Emerging Infections
Product Development for Public Health & Emerging Infections Michael G Kurilla, MD-PhD Director, Office of BioDefense Research Affairs Division of Microbiology & Infectious Diseases Associate Director,
More informationAdvancing Wound Care. December 2011
December 2011 Forward Looking Statements Statements contained in this presentation that are not statements of historical fact may be deemed to be forward looking statements. Without limiting the generality
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationFor personal use only
ASX:NRT NASDAQ:NVGN Novogen Ltd (Company) MARKET RELEASE 12 September 2016 NOVOGEN PRESENTS AT RODMAN & RENSHAW CONFERENCE ABN 37 063 259 754 Capital Structure Ordinary Shares on issue: 429 M Board of
More informationCardioPharma. CP-101 CardiaPill The Game Changer in Treating CVD
1 CardioPharma CP-101 CardiaPill The Game Changer in Treating CVD 2 Forward looking statements This presentation includes forward-looking statements including statements regarding the timing and outcome
More informationDiagnosing wound infection - a clinical challenge
Diagnosing wound infection - a clinical challenge Keith F Cutting Merimbula, 5 th November 2010 Wound infection microbial load immune system microbial load + + + immune system infection host response Diagnosing
More informationFor personal use only. A new company with: a new technology platform for cancer drug development a new management team a new Board
A new company with: a new technology platform for cancer drug development a new management team a new Board Disclaimer This presentation is confidential and is not an offer or a recommendation or intended
More informationAdjunctive Therapies: The Use of Skin Substitutes and Growth Factors in Venous Leg Ulceration (VLU)
Adjunctive Therapies: The Use of Skin Substitutes and Growth Factors in Venous Leg Ulceration (VLU) Sami Khan, MD FACS Associate Professor of Surgery Division of Plastic and Reconstructive Surgery SUNY-Stony
More informationContacts. Chronos Therapeutics. Dr Huw Jones, CEO Dr Helen Kuhlman, VP Corporate Development Tel: +44 (0)
PRESS RELEASE Chronos Therapeutics Strengthens Management Team with Appointment of Dr Fraser Murray and Dr Timothy Schulz-Utermoehl as Vice Presidents of Pre-Clinical Development Oxford, UK, 4th August
More information1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Diabetic Foot Ulcer Therapeutics - Introduction 2.1 Overview Diabetic Foot Ulcer
1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Diabetic Foot Ulcer Therapeutics - Introduction 2.1 Overview 2.1.1 Diabetic Foot Ulcer Classification Systems 2.2 Epidemiology 2.2.1 Historic
More information5/1/2015 SEPSIS SURVIVING SEPSIS CAMPAIGN HOW TO APPROACH THE POSSIBLE SEPTIC CHILD 2015 INFECTION CAN BE CONFIRMED BY:
SURVIVING SEPSIS CAMPAIGN HOW TO APPROACH THE POSSIBLE SEPTIC CHILD 2015 Omer Nasiroglu MD Baptist Children s Hospital Pediatric Emergency Department SEPSIS IS A SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
More informationCorporate Presentation
Corporate Presentation February 2, 2017 NASDAQ: GALT www.galectintherapeutics.com 2017 Galectin Therapeutics Inc. Forward-Looking Statements This presentation contains, in addition to historical information,
More informationMartin Friede Vaccine workstream Liz Tayler AMR secretariat Global action plan on antimicrobial resistance
WHO Global Action Plan on Antimicrobial Resistance Martin Friede Vaccine workstream Liz Tayler AMR secretariat AMR a global health threat Resistant bacterial infections cause about 50 000 deaths in the
More informationBlood testing at your finger tips. Know Now. No waiting. A pocket laboratory for the 21 st century
Blood testing at your finger tips. Know Now. No waiting. A pocket laboratory for the 21 st century 1 Blood testing is a huge global high growth market Driving Market Growth: $51.8 billion $60.6 billion
More informationSAMPLE. HLTEN406A Undertake basic wound care. Learner resource. HLT07 Health Training Package. Version 2
HLT07 Health Training Package HLTEN406A Undertake basic wound care Learner resource Version 2 Training and Education Support Industry Skills Unit Meadowbank Acknowledgments The TAFE NSW Training and Education
More informationDIRECT SPINAL THERAPEUTICS INC.
DIRECT SPINAL THERAPEUTICS INC. Novel Spinal Cord Modulation Platform Overview Presentation May 2014 Direct Spinal Therapeutics Inc. (DSTI) Proprietary Neuromodulation product/platform originated at Univ.
More informationMultiple Interventions for Diabetic Foot Ulcer Treatment Trial (MIDFUT)
Multiple Interventions for Diabetic Foot Ulcer Treatment Trial (MIDFUT) Nikki Dewhirst MIDFUT Clinical Co-ordinator, Clinical Trials Research Unit, University of Leeds Senior Vascular Research Nurse, Leeds
More informationInterim Results for 6 Months Ended 31 March 2017 and Business Update. 17 th May 2017
Interim Results for 6 Months Ended 31 March 2017 and Business Update 17 th May 2017 Forward-looking Statements Please Note This presentation includes forward-looking statements. These forward-looking statements
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION NASDAQ: GALT www.galectintherapeutics.com 1 Forward-Looking Statements This presentation contains, in addition to historical information, forward-looking statements within the meaning
More informationCorporate Overview NASDAQ: CLRB
Corporate Overview NASDAQ: CLRB Safe Harbor Statement 2 This presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this
More informationDevelopment of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE)
Development of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE) Dr. Juliane Bernholz, Novartis (Coordinator) Dr. Andrea Appenzeller,
More informationUEMS & EBS: DIVISION OF TRANSPLANT SURGERY
CURRICULUM AND SYLLABUS TRANSPLANTATION Module 1: Multi-organ retrieval Ability to evaluate donor suitability Ability to retrieve abdominal organs for transplantation Evaluation of donor/ organs suitability
More informationCOMPANY PRESENTATION July 2018
COMPANY PRESENTATION July 2018 Forward looking Statement This presentation contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S.
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationDiscovery of Potent, Highly Selective, Broad Spectrum Antivirals
Discovery of Potent, Highly Selective, Broad Spectrum Antivirals Fred Hutch/Merck Infectious Disease Summit May 10, 2018 Sam Lee, Ph.D. 1 Forward Looking Statements This presentation contains forward-looking
More informationPioneering Innovative Therapies for Liver Disease
Pioneering Innovative Therapies for Liver Disease Investor Presentation January 2017 Forward-Looking Statements This document contains forward-looking statements made pursuant to the safe harbor provisions
More informationBIOSORB GELLING FIBRE DRESSING. Key facts: In vitro evidence
BIOSORB GELLING FIBRE DRESSING Key facts: In vitro evidence BIOSORB Gelling Fibre Dressing WHAT IS IT? BIOSORB Gelling Fibre Dressing is a soft, conformable non-woven dressing made from sodium carboxymethyl
More informationRSM. Indications For Use
NEXT GENERATION SOLUTIONS RSM PATRIOT-RSM Amniotic Allograft Membrane is a human placental-based tissue product. The membrane forms a protective covering over the wound while providing the key components
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationTransforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017
Transforming patients lives through cellular immunotherapy Next Generation Cellular Immunotherapy June 2017 1 Overview of Cell Medica Mission: Transform the treatment of cancer with cellular immunotherapy
More informationCorporate Presentation. March 2018
OTCQB: ONCX Breakthrough technology for women s cancers Corporate Presentation March 2018 Oncolix 2018 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute
More informationWright Medical Technology, Inc Airline Road Arlington, TN phone toll-free
References 1 Brigido SA, Boc SF, Lopez RC. Effective Management of Major Lower Extremity Wounds Using an Acellular Regenerative Tissue Matrix: A Pilot Study. Orthopedics 2004; 27(1S): pp145-149. 2 Brigido
More information